Managed Healthcare Executive July 30, 2024
Humira and Sterlara are still the mainstays of spending, but Vizient that expenditures on drugs that treat genetic disorders will climb to $25 billion in 2026,
Nine treatment for genetic disorders could be approved this year and next as the expensive therapies that work at the genetic level become more common, straining budgets, according to a Vizient report on drug expenditures.
Familiar drugs such as Humira (adalimumab), Stelara (ustekinumab), Keytruda (pembrolizumab) and now semaglutide (sold as Ozempic for diabetes and as Wegovy for weight loss) continue to top the list of drug expenditures by Vizient’s hospital and nonacute clients. The list of drugs that Vizient projects will have the largest price hikes in 2025 also includes some familiar names: Prolia...
Today's Sponsors
Today's Sponsor